A detailed history of Edge Rock Capital LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Edge Rock Capital LLC holds 155 shares of VRTX stock, worth $74,074. This represents 0.06% of its overall portfolio holdings.

Number of Shares
155
Holding current value
$74,074
% of portfolio
0.06%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 24, 2024

BUY
$392.81 - $485.53 $60,885 - $75,257
155 New
155 $72,000
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $9,947 - $11,909
29 New
29 $11,000
Q3 2022

Oct 14, 2022

BUY
$273.83 - $305.53 $4,381 - $4,888
16 New
16 $5,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $123B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Edge Rock Capital LLC Portfolio

Follow Edge Rock Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edge Rock Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Edge Rock Capital LLC with notifications on news.